APLS - Apellis Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

APLS is currently covered by 20 analysts with an average price target of $38. This is a potential upside of $14.1 (59%) from yesterday's end of day stock price of $23.9.

Apellis Pharmaceuticals's activity chart (see below) currently has 250 price targets and 287 ratings on display. The stock rating distribution of APLS is 63.43% BUY and 36.57% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 64.1% with an average time for these price targets to be met of 187.36 days.

Highest price target for APLS is $57, Lowest price target is $18, average price target is $42.42.

Most recent stock forecast was given by YIGAL NOCHOMOVITZ from CITI on 29-Jul-2025. First documented stock forecast 04-Dec-2017.

Currently out of the existing stock ratings of APLS, 85 are a BUY (63.43%), 49 are a HOLD (36.57%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$46

$21.67 (89.07%)

$41

14 days ago
(29-Jul-2025)

20/26 (76.92%)

$27.05 (142.74%)

216

Hold

$24

$-0.33 (-1.36%)

$23

27 days ago
(16-Jul-2025)

5/10 (50%)

$4.25 (21.52%)

29

Hold

$29

$4.67 (19.19%)

$26

2 months 10 days ago
(02-Jun-2025)

8/13 (61.54%)

$9.86 (51.52%)

111

Hold

$20

$-4.33 (-17.80%)

$30

2 months 29 days ago
(14-May-2025)

5/11 (45.45%)

$3.3 (19.76%)

60

Buy

$52

$27.67 (113.73%)

$106

3 months 3 days ago
(09-May-2025)

2/17 (11.76%)

$34.7 (200.58%)

570

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is APLS (Apellis Pharmaceuticals) average time for price targets to be met?

On average it took 187.36 days on average for the stock forecasts to be realized with a an average price target met ratio 64.1

Which analyst has the current highest performing score on APLS (Apellis Pharmaceuticals) with a proven track record?

STEVEN SEEDHOUSE

Which analyst has the most public recommendations on APLS (Apellis Pharmaceuticals)?

Steven Seedhouse works at RAYMOND JAMES and has 7 price targets and 5 ratings on APLS

Which analyst is the currently most bullish on APLS (Apellis Pharmaceuticals)?

Madhu Kumar with highest potential upside - $116.67

Which analyst is the currently most reserved on APLS (Apellis Pharmaceuticals)?

Luca Issi with lowest potential downside - -$6.33

Apellis Pharmaceuticals in the News

Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target

We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the best-performing stocks on Thursday. Apellis Pharmaceuticals surged by 17.58 percent on Thursday to close at $22.34 apiece as investors took path from an investment firm’s price target increase for its stock. In a market note on Wednesday, Scotiabank...

Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say

Apellis Pharmaceuticals, Inc. (APLS) reported $178.49 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 10.6%. EPS of -$0.33 for the same period compares to -$0.28 a year ago. The reported revenue represents a surprise of -6.35% over the Zacks Consensus Estimate of $190.59 million. With the consensus EPS estimate...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?